Introduction: Biologics have revolutionized the therapy of moderate-to-severe plaque psoriasis. Yet, despite their greater efficacy over conventional systemic therapies their high cost has represented a burden for healthcare systems, which limited their use. More recently, the availability of several biosimilars at low cost is changing the...
-
2020 (v1)PublicationUploaded on: April 14, 2023
-
2023 (v1)Publication
Purpose: Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index...
Uploaded on: February 14, 2024